People: Illumina Inc (ILMN.O)

Summary

Name	Age	Since	Current Position
William Rastetter	64	2005	Chairman of the Board
Jay Flatley	60	1999	President, Chief Executive Officer, Director
Marc Stapley	43	2012	Chief Financial Officer, Senior Vice President
David Walt	60	1998	Chairman - Scientific Advisory Board, Independent Director
Mostafa Ronaghi	44	2008	Chief Technology Officer, Senior Vice President
Charles Dadswell		2013	Senior Vice President, General Counsel, Secretary
Gregory Heath	55	2008	Senior Vice President, General Manager - Diagnostics
Christian Henry	45	2012	Senior Vice President, General Manager - Genetic Analysis
Mark Lewis	60	2012	Senior Vice President, General Manager - Molecular Biology and PCR
Matthew Posard	46	2012	Senior Vice President, General Manager - Translational and Consumer Genomics
Paul Bianchi	51	2012	Senior Vice President - Human Resources
Nicholas Naclerio	52	2011	Senior Vice President - Corporate and Venture Development
Tristan Orpin	47	2010	Chief Commercial Officer, Senior Vice President
A. Blaine Bowman	66	2007	Independent Director
Daniel Bradbury	51	2004	Independent Director
Karin Eastham	63	2004	Independent Director
Robert Epstein	57	2012	Independent Director
Paul Grint		2005	Independent Director
Gerald Moller	69	2010	Independent Director
Roy Whitfield	59	2007	Independent Director
Rebecca Chambers			Senior Director - Investor Relations

» Insider Trading

Biographies

Name	Description
William Rastetter	Dr. William H. Rastetter, Ph.D., is Chairman of the Board of Illumina Inc., since January 2005. Dr. Rastetter is a co-founder of Receptos, Inc., a privately-held drug discovery and development company, and has been serving as Chairman of the Board since 2009. Dr. Rastetter serves as Chairman of Neurocrine Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on neurological and endocrine diseases and disorders, a director of Regulus Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company, and Chairman of Fate Therapeutics, a privately-held company focused on developing stem cell therapeutics. Dr. Rastetter served as a partner of Venrock Associates, a venture capital company from 2006 until February 2013. From 2007 to 2009, Dr. Rastetter was Chief Executive Officer and the Executive Chairman of Apoptos, Inc., a privately-held oncology research and development company, which was acquired by Receptos in 2009. At the end of 2005, Dr. Rastetter retired as the Executive Chairman of Biogen Idec Inc., a biopharmaceutical company. He had served in this position since the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. He served as Chief Executive Officer of IDEC Pharmaceuticals, a biotechnology company, from 1986 to 2003 and as Chairman of its Board of Directors from 1996 to 2003. Additionally, he served as President of IDEC Pharmaceuticals from 1986 to 2002, and as Chief Financial Officer from 1988 to 1993. From 1982 to 1986, Dr. Rastetter served in various positions at Genentech, Inc., a biotechnology company, and previously he was an associate professor at the Massachusetts Institute of Technology. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.
Jay Flatley	Mr. Jay T. Flatley is President, Chief Executive Officer, Director of Illumina Inc., since October 1999. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director of Coherent, Inc., a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.
Marc Stapley	Mr. Marc A. Stapley has been appointed Chief Financial Officer, Senior Vice President of Illumina Inc., effective January 20, 2012. Mr. Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Mr. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.
David Walt	Dr. David R. Walt, Ph.D., is Chairman - Scientific Advisory Board, Independent Director of Illumina Inc., since June 1998. Dr. Walt has been the Robinson Professor of Chemistry at Tufts University since 1995 and has been a Howard Hughes Medical Institute Professor since 2006. Dr. Walt is a Member of the National Academy of Engineering, a Fellow of the American Institute of Medical and Biological Engineers, and a Fellow of the American Association for the Advancement of Science. Dr. Walt has published over 250 papers and is named as an inventor or co-inventor of over 60 patents, many of which are directed to micro-array products. He also serves as a board member for Quanterix, Inc., a privately-held company focused on single molecule analysis for clinical diagnostics, and AuraSense, LLC, a privately-held company focused on developing therapeutic agents based on spherical nucleic acids. Dr. Walt holds a B.S. in Chemistry from the University of Michigan and received his Ph.D. in Chemical Biology from SUNY at Stony Brook.
Mostafa Ronaghi	Dr. Mostafa Ronaghi, Ph.D., is Chief Technology Officer, Senior Vice President of Illumina Inc. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc., a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.
Charles Dadswell	Mr. Charles Dadswell has been appointed as Senior Vice President, General Counsel, Secretary of Illumina Inc., effective April 22, 2013. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor's in science from Ferris State University.
Gregory Heath	Dr. Gregory F. Heath, Ph.D., is Senior Vice President, General Manager - Diagnostics of Illumina Inc. Dr. Heath joined Illumina in March 2008 and is responsible for managing Illumina’s emerging diagnostics business, specifically overseeing the development of diagnostic content for the BeadXpress system, and ultimately for Illumina’s sequencing platform; 2004 – 2008: senior vice president for Roche Molecular Systems, Inc., responsible for its global molecular diagnostics business (2006-2008), global marketing and business development (2005-2006), and global product marketing (2004-2005).
Christian Henry	Mr. Christian O. Henry is Senior Vice President, General Manager - Genetic Analysis of Illumina Inc. He resigned as Chief Financial Officer effective January 4, 2012. He served as Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010; Senior Vice President and Chief Financial Officer from 2006 to 2009; 2006 – 2009: Senior Vice President and Chief Financial Officer;2005 – 2006: Vice President and Chief Financial Officer;2003 – 2005: chief financial officer for Tickets.com, a publicly traded, online ticket provider that was acquired by Major League Baseball Advanced Media, LP; Joined Illumina 2005.
Mark Lewis	Mr. Mark L. Lewis has been appointed as Senior Vice President & General Manager - Molecular Biology and PCR of Illumina, Inc. He was vice president, special order research products and general manager at BD Biosciences from 2002 to 2008. From 1992 to 2002, Mark held various technical, commercial, and management positions at Molecular Dynamics, including Vice President of Sequencing Technology. In that capacity, he led research and development efforts in DNA sequencing and Genotyping. Mark earned a Bachelor of Arts degree in Biology from the University of California, San Diego.
Matthew Posard	Mr. Matthew L. Posard is Senior Vice President, General Manager - Translational and Consumer Genomics of Illumina, Inc. He was Vice President, Global Sales from 2007 – 2012; Vice President, Marketing from 2006 – 2007. He joined Illumina 2006.
Paul Bianchi	Mr. Paul L. Bianchi is Senior Vice President - Human Resources of Illumina, Inc., since September 5, 2012. From 2009 to 2012 he served as senior vice president, human resources at Risk Management Solutions, Inc. 2005 – 2009: principal at Strayer Consulting Group, Inc.
Nicholas Naclerio	Dr. Nicholas J. Naclerio, Ph.D., is Senior Vice President - Corporate and Venture Development of Illumina, Inc. He was executive chairman of True Materials, a privately-held life science company that was acquired by Affymetrix, Inc. from 2007 – 2008; chief executive officer of ParAllele BioScience, Inc., a privately-held life science company that was acquired by Affymetrix, Inc. from 2003 – 2005. Mr. Naclerio became a named executive officer in fiscal 2011. He joined Illumina 2010.
Tristan Orpin	Mr. Tristan B. Orpin is Chief Commercial Officer, Senior Vice President of Illumina Inc. He was Senior Vice President, Commercial Operations from 2007 – 2010; Vice President of Worldwide Sales from 2002 – 2007. He joined Illumina 2002.
A. Blaine Bowman	Mr. A. Blaine Bowman is Independent Director of Illumina Inc., since January 2007. Mr. Bowman was formerly the Chairman, President, and Chief Executive Officer of Dionex Corporation, a NASDAQ-listed manufacturer of analytical instruments. Mr. Bowman retired as President and Chief Executive Officer of Dionex in 2002 and as Chairman of the Board in 2005, and he remained a director of Dionex until its sale to Thermo Fisher Scientific Inc. in 2011. He joined Dionex in 1977 and was named President and Chief Executive Officer in 1980. Before joining Dionex, Mr. Bowman was a management consultant with McKinsey & Company, a management consulting firm, and a product engineer with Motorola Semiconductor Products Division, a communication equipment company. Mr. Bowman also serves as a director of Altera Corporation, a NASDAQ-listed provider of programmable logic solutions, and ProteinSimple, a privately-held life sciences company focused on protein research through the use of nanoproteomics. He also served as a past director of Molecular Devices Corporation, a NASDAQ-listed supplier of instruments and consumables for life science researchers, from 1985 until its sale to MDS Inc. in 2007, and of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Bowman received his B.S. in Physics from Brigham Young University and an M.B.A. from Stanford University.
Daniel Bradbury	Mr. Daniel M. Bradbury is Independent Director of Illumina Inc., since January 2004. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2007 until its acquisition by Bristol-Myers-Squibb Company in 2012. From 2006 until 2012, he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin’s President (2006-2007), Chief Operating Officer (2003-2006), and Executive Vice President (2000-2003). He joined Amylin in 1994 and also held officer-level positions in Corporate Development and Marketing. From 1984 to 1994, Mr. Bradbury held a number of sales and marketing positions at SmithKline Beecham Pharmaceuticals, a global pharmaceutical manufacturer. Mr. Bradbury serves as a director of Corcept Therapeutics Incorporated, a NASDAQ-listed biopharmaceutical company, Geron Corporation, a NASDAQ-listed biopharmaceutical company, BioMed Realty Trust, Inc., a NYSE-listed real estate investment trust, and Castle Biosciences Inc., a privately-held molecular diagnostics company. Mr. Bradbury also serves on the BioMed Ventures Advisory Committee, the Investor Growth Capital Advisory Committee, the Keck Graduate Institute’s Board of Trustees, the UCSD Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, and the University of Miami’s Diabetes Research Institute Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.
Karin Eastham	Ms. Karin Eastham, CPA, is Independent Director of Illumina Inc., since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc., a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc., a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc., a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc., a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.
Robert Epstein	Dr. Robert S. Epstein, M.D., has been appointed as Independent Director of Illumina, Inc., effective November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc., a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.
Paul Grint	Dr. Paul C. Grint, M.D., is no longer Independent Director of Illumina Inc., effective May 29, 2013. Dr. Grint is currently President of Cerexa, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc., a pharmaceutical company. Prior to joining Cerexa, Dr. Grint served as Senior Vice President at Forest Research Institute, Inc., the scientific development subsidiary of Forest Laboratories, Inc. Prior to joining Forest Laboratories, from 2006 to 2008 Dr. Grint was Chief Medical Officer at Kalypsys Inc., a biopharmaceutical company, and during 2006 he was Senior Vice President and Chief Medical Officer at Zephyr Sciences, Inc, a biopharmaceutical company. He has held similar executive positions at Pfizer Inc., IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation. Dr. Grint began his pharmaceutical career at the Wellcome Research Laboratories in the UK and received his medical degree from the University of London, St. Bartholomew’s Hospital Medical College in London. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or co-author of over 50 publications.
Gerald Moller	Dr. Gerald Moller, Ph.D., is Independent Director of Illumina, Inc., since July 2010. Dr. Möller is currently an advisor at HBM Bio Ventures AG, a Swiss investment firm focusing on biotechnology, emerging pharmaceutical, medical technology, and related industries. Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan, and the United States, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and chief executive officer of Boehringer Mannheim Therapeutics. In 1995 he became chief executive officer of the worldwide Boehringer Mannheim Group. Following Boehringer’s acquisition by Roche in 1998, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche where he served until the end of 1998. In addition to Illumina, Dr. Möller sits on several life sciences and diagnostics boards, including Morphosys AG, a Frankfurt Stock Exchange-listed biotechnology company; Bionostics, Inc., a privately-held developer and manufacturer of calibrators and quality control products for diabetes diagnostics test systems; Invendo-Medical GmbH, a privately-held medical technology company; Adrenomed AG, a privately-held biopharmaceutical company; and Definiens AG, a privately-held provider of image analysis for digital pathology. Dr. Möller served as a past director of Vivacta Limited, a privately-held medical diagnostics company, until its sale to Novartis AG in December 2012. Dr. Möller also is vice-chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.
Roy Whitfield	Mr. Roy A. Whitfield is Independent Director of Illumina Inc., since January 2007. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (formerly Incyte Genomics), a NASDAQ-listed drug discovery and development company he co-founded in 1991. From 1993 to 2001, Mr. Whitfield served as its Chief Executive Officer and, from November 2001 until his retirement in June 2003, as its Chairman. Mr. Whitfield remains on the board of Incyte Corporation. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Earlier, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. In addition to serving on the Incyte Board, since 2000 he has served as a director of Nektar Therapeutics, a NASDAQ-listed clinical-stage biopharmaceutical company, and he also serves as a director of Station X Inc., a privately-held developer of software products for analyzing largescale human genome information. Mr. Whitfield also served as a past director of Solexa, Inc. from 2006 until its sale to Illumina in 2007. Mr. Whitfield received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.
Rebecca Chambers

Basic Compensation

Name	Fiscal Year Total
William Rastetter	--
Jay Flatley	8,171,080
Marc Stapley	3,951,480
David Walt	--
Mostafa Ronaghi	2,079,570
Charles Dadswell	--
Gregory Heath	1,674,860
Christian Henry	2,708,140
Mark Lewis	--
Matthew Posard	2,886,490
Paul Bianchi	2,586,580
Nicholas Naclerio	3,778,690
Tristan Orpin	2,155,820
A. Blaine Bowman	--
Daniel Bradbury	--
Karin Eastham	--
Robert Epstein	--
Paul Grint	--
Gerald Moller	--
Roy Whitfield	--
Rebecca Chambers	--

As Of 29 Dec 2012

Options Compensation

Name	Options	Value
William Rastetter	0	0
Jay Flatley	545,000	3,821,096
Marc Stapley	0	0
David Walt	0	0
Mostafa Ronaghi	0	0
Charles Dadswell	0	0
Gregory Heath	0	0
Christian Henry	96,500	2,650,530
Mark Lewis	0	0
Matthew Posard	0	0
Paul Bianchi	0	0
Nicholas Naclerio	0	0
Tristan Orpin	163,001	5,409,140
A. Blaine Bowman	0	0
Daniel Bradbury	0	0
Karin Eastham	0	0
Robert Epstein	0	0
Paul Grint	0	0
Gerald Moller	0	0
Roy Whitfield	0	0
Rebecca Chambers	0	0

Insider Trading

Name	Shares Traded	Price
RONAGHI MOSTAFA	20,000	$68.71
RONAGHI MOSTAFA	20,000	$44.38
RONAGHI MOSTAFA	2,500	$69.34
RONAGHI MOSTAFA	1,500	$69.54
ORPIN TRISTAN B	20,000	$70.00
NACLERIO NICHOLAS	15,000	$75.00
NACLERIO NICHOLAS	10,000	$70.00
NACLERIO NICHOLAS	10,000	$43.37
NACLERIO NICHOLAS	15,000	$43.37
ORPIN TRISTAN B	5,000	$68.00
FLATLEY JAY T	20,000	$66.63
FLATLEY JAY T	20,000	$10.49
ORPIN TRISTAN B	5,000	$20.04
ORPIN TRISTAN B	5,000	$65.68
WALT DAVID R	5,000	$64.15
ORPIN TRISTAN B	5,000	$20.04
STAPLEY MARC A	15,000	$36.30
NACLERIO NICHOLAS	10,000	$65.00
ORPIN TRISTAN B	5,000	$65.00
NACLERIO NICHOLAS	10,000	$43.37
STAPLEY MARC A	15,000	$65.00
FLATLEY JAY T	10,000	$10.49
FLATLEY JAY T	10,000	$62.61
RONAGHI MOSTAFA	12,500	$37.04
RONAGHI MOSTAFA	6,500	$28.45

» Full list on Insider Trading

People: Illumina Inc (ILMN.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: